Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study

Documents similaires

• Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
  par: Yu‐Nan Huang, et autres
  Publié: (2024)
• Front Cover
  par: Chia‐Ming Lin, et autres
  Publié: (2025)
• Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
  Publié: (2025)
• Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide ‐1 receptor agonists among people with diabetes: A propensity‐score matching study
  par: Yuta Suzuki, et autres
  Publié: (2024)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  par: Yunwen Xu, et autres
  Publié: (2025)